Comments
Kerala-based Agappe Diagnostics Ltd has received a patent for the indigenously developed Mispa i3, a compact and affordable diagnostic instrument, which helps with early diagnosis and clinical management of a variety of diseases, such as diabetes, cardiovascular risk, inflammation, and kidney disease.
P Rajeeve, the State Industries Minister, unveiled the patent certificate awarded to Mispa i3 at the company’s corporate office in Pattimattom.
Mispa i3 is an automated cartridge-based specific protein analyzer. It uses pre-filled, bar-coded, ready-to-use individual test cartridges. The instrument could quantitate twenty-five different protein parameters in the blood.
Related Stories
Prannoy, Radhika Roy resign as directors of NDTV promoter group
Yesterday, the founders issued shares to a unit of Adani Group, taking the conglomerate a step closer to taking over the media firm“We have developed necessary reagents through indigenous R&D. The range of parameters is matchless. It guarantees contamination-free testing. The smart card-based calibration reduces reagent consumption with increased accuracy. This is our flagship product,” Thomas John, Managing Director, Agappe Diagnostics said.
Mispa i3 had earlier received Technology Award instituted by the Technology Development Board, Department of Science and Technology.
Related Stories
Singapore sourcing nurses from outside including India
Singapore is attempting to replace nurses lost to other nations during the pandemicMispa i3 is designed and developed by Agappe considering the medium laboratories and the rural population in India. The automated platforms available from multinational companies are huge systems with high prices, Thomas John said.
The company has also announced future expansion projects at Kinfra, Kakkanad and its upcoming projects in collaboration with leading multinational companies.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.